MSMonika Słowińska

Monika Słowińska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Monika Słowińska has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk Factors Associated with Refractory Epilepsy in Patients with Tuberous Sclerosis Complex: A Systematic Review

    by Dominika Miszewska, Monika Sugalska, Sergiusz Jóźwiak

    Background: Epilepsy affects 70–90% of patients with tuberous sclerosis complex (TSC). In one-third of them, the seizures become refractory to treatment. Drug-resistant epilepsy (DRE) carries a significant educational, social, cognitive, and economic burden. Therefore, determining risk factors that increase the odds of refractory seizures is needed. We reviewed current data on risk factors associated with DRE in patients with tuberous sclerosis. Methods: The review was performed according to the PRISMA guidelines. Embase, Cochrane Library, MEDLINE, and ClinicalTrial.gov databases were searched. Only full-text journal articles on patients with TSC which defined risk factors related to DRE were included. Results: Twenty articles were identified, with a cohort size between 6 and 1546. Seven studies were prospective. Three factors appear to significantly increase DRE risk: TSC2 mutation, infantile spasms, and a high number of cortical tubers. Conclusions: A proper MRI and EEG monitoring, along with genetic testing, and close observation of individuals with early onset of seizures, allow identification of the patients at risk of DRE.


  • Open Access

    Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries

    by Monika Słowińska, Katarzyna Kotulska, Sylwia Szymańska, Steven L. Roberds, Carla Fladrowski, Sergiusz Jóźwiak


  • Oral Findings in Children, Adolescents and Adults with Tuberous Sclerosis Complex

    by Emil Korporowicz, Dorota Olczak-Kowalczyk, Maja Lipiec, Monika Słowińska, Dariusz Gozdowski, Sergiusz Jóźwiak

    Objectives: Tuberous sclerosis complex (TSC) is a multisystem genetic disorder characterized by the development of benign tumors. The aim of the study was to assess the prevalence of oral lesions in patients with TSC and healthy individuals. Study design: The study included 120 patients aged 1.1 to 42.7 years: 60 patients with TSC and 60 controls. Clinical assessment of oral hygiene (Plaque Index–PLI), gingiva (Gingival Index–GI, Gingival Overgrowth Index–GOI), oral mucosa and dentition (caries, tooth wear, enamel defects) was performed. Statistical analysis was performed. Results: 40 patients with TSC received anticonvulsants. Neglected hygiene (PLI: 1.50±0.96 vs 0.92±0.72), gingival hyperplasia (50.0% vs.1.7%), gingivitis (80.7% vs. 53.4%), oral mucosal fibromas (10.0% vs. 0.0%), mucous membrane traumatic lesions (11.7% vs. 1.7%), enamel pits and hypoplasia of incisal borders (41.7% vs. 6.7%), tooth wear (35.0% vs. 11.7%) were more common in patients with TSC compared to controls; increased gingival hyperplasia was correlated with vigabatrin and levetiracetam treatment (r = 0.266 and 0.279, respectively), gingivitis was correlated with PLI (r= 0.635). Conclusions: Although gingival fibromas in TSC are independent of patient’s age, young age, anticonvulsant therapy and local factors increase their severity. Enamel defects in TSC include pits, but also enamel loss on the incisal edges and tooth wear.


  • Open Access

    Preventive Antiepileptic Treatment in Tuberous Sclerosis Complex: A Long-Term, Prospective Trial

    by Sergiusz Jozwiak, Monika Słowińska, Julita Borkowska, Krzysztof Sadowski, Barbara Łojszczyk, Dorota Domańska-Pakieła, Dariusz Chmielewski, Magdalena Kaczorowska-Frontczak, Jagoda Głowacka, Kamil Sijko, et al.


  • Emerging treatments and therapeutic targets for tuberous sclerosis complex in children

    by Monika Słowińska, Sergiusz Jóźwiak

    Introduction: Tuberous sclerosis complex (TSC) is a genetic disease affecting 1:6000 newborns. It is a multisystem disease caused by overactivation of mechanistic target of rapamycin (mTOR) pathway and associated with the development of many benign tumors in different organs (e.g. brain, skin, kidney, lungs, heart) and comorbidities including epilepsy, cognitive impairment, neuropsychiatric disorders. In recent years, some new therapeutic agents and strategies have emerged for TSC. Areas covered: In the article, authors discuss the results of recent studies particularly on epilepsy management including preventive antiepileptic treatment in TSC infants, current studies on cannabidiol, and an increasing role of mTOR inhibitors (sirolimus, everolimus) in the treatment of many TSC manifestations. Expert opinion: Recent years and studies resulted in significant progress in the therapy of TSC. Prevention of epilepsy in TSC children with subsequent improvement of cognitive outcome is currently possible. The question about the duration of preventive treatment in children who did not experience seizures will still be open. Considering the increasing role of mTOR inhibitors, the possibility of not only therapeutic but also preventive role of these drugs for TSC manifestations may be a question for future research.

  • Problems of nephrooncology. Proceedings from the 1st Scientific and Training Conference Nephrooncology 5–6 October 2018, Gdańsk, Poland

    by Teresa Bączkowska, John J. Bissler, Katarzyna Błasińska‑Przerwa, Jacek Borawski, Jerzy Chudek, Kazimierz Ciechanowski, Bożena Czarkowska‑Pączek, Alicja Dębska-Ślizień, Maciej Domański, Magdalena Durlik, et al.


  • Prevention of epilepsy in humans – truth or myth? The experience from Sturge-Weber syndrome and Tuberous Sclerosis Complex

    by Monika Słowińska, Weronika Golec, Sergiusz Jóźwiak

    Introduction. Epilepsy is a chronic neurological disease, usually decreasing the quality of life and often resulting in other comorbidities e.g. cognitive impairment in children. Despite the recent discovery of new antiepileptic drugs, roughly one in three patients suffers from drug-resistant seizures. Therefore, the prevention of epilepsy is becoming one of the most important challenges in medicine. Is it, however, in fact possible to prevent epilepsy? Clinical reflections and implications. We present the results of preventive antiepileptic treatment in children with Sturge-Weber syndrome and Tuberous Sclerosis Complex as examples of the possible prevention of epilepsy and epilepsy-associated cognitive impairment in children. Introduction. Epilepsy is a chronic neurological disease, usually decreasing the quality of life and often resulting in other comorbidities e.g. cognitive impairment in children. Despite the recent discovery of new antiepileptic drugs, roughly one in three patients suffers from drug-resistant seizures. Therefore, the prevention of epilepsy is becoming one of the most important challenges in medicine. Is it, however, in fact possible to prevent epilepsy? Clinical reflections and implications. We present the results of preventive antiepileptic treatment in children with Sturge-Weber syndrome and Tuberous Sclerosis Complex as examples of the possible prevention of epilepsy and epilepsy-associated cognitive impairment in children.


  • Current concepts on epilepsy management in tuberous sclerosis complex

    by Maria Paola Canevini, Katarzyna Kotulska‐Jozwiak, Paolo Curatolo, Francesca La Briola, Angela Peron, Monika Słowińska, Jolanta Strzelecka, Aglaia Vignoli, Sergiusz Jóźwiak

    Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disease affecting approximately 1 in 6,000 people, and represents one of the most common genetic causes of epilepsy.Epilepsy affects 90% of the patients and appears in the first 2 years of life in the majority of them. Early onset of epilepsy in the first 12 months of life is associated with high risk of cognitive decline and neuropsychiatric problems including autism.Prenatal or early infantile diagnosis of TSC, before the onset of epilepsy, provides a unique opportunity to monitor EEG before the onset of clinical seizures, thus enabling early intervention in the process of epileptogenesis.In this review, we discuss the current status of knowledge on epileptogenesis in TSC, and present recommendations of American and European experts in the field of epilepsy.


  • Open Access

    Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?

    by Monika Słowińska, Sergiusz Jóźwiak, Angela Peron, Julita Borkowska, Dariusz Chmielewski, Krzysztof Sadowski, Elżbieta Jurkiewicz, Aglaia Vignoli, Francesca La Briola, Maria Paola Canevini, et al.

    Tuberous sclerosis complex (TSC) is a genetic disorder with an incidence of 1:6000 live births and associated with the development of benign tumors in several organs. It is also characterized by high rates of neurological and neuropsychiatric abnormalities, including epilepsy affecting 70–90% of patients and being one of the major risk factors of intellectual disability. The first seizures in TSC patients appear usually between the 4th and the 6th months of life. Recent studies have shown the beneficial role of preventative antiepileptic treatment in TSC patients, with the possibility for improvement of cognitive outcome. Moreover, European recommendations suggest early introduction of Vigabatrin if ictal discharges occur on EEG recordings, with or without clinical manifestation. The aim of this study was to define the most useful approach to make the diagnosis of TSC before seizure onset (before age 4th months), in order to start early EEG monitoring with possible preventative treatment intervention. We performed a retrospective review of children who were suspected of having TSC due to single or multiple cardiac tumors as the first sign of the disease. We analyzed the medical records in terms of conducted clinical tests and TSC signs, which were observed until the end of the 4th month of age. Subsequently, we described the different clinical scenarios and recommendations for early diagnosis. 82/100 children were diagnosed with TSC within the first 4 months of life. Apart from cardiac tumors, the most frequently observed early TSC signs were subependymal nodules (71/100, 71%), cortical dysplasia (66/100, 66%), and hypomelanotic macules (35/100, 35%). The most useful clinical studies for early TSC diagnosis were brain magnetic resonance imaging (MRI), skin examination and echocardiography. Genetic testing was performed in 49/100 of the patients, but the results were obtained within the first 4 months of life in only 3 children. Early diagnosis of TSC, before seizure onset, is feasible and it is becoming pivotal for epilepsy management and improvement of cognitive outcome. Early TSC diagnosis is mostly based on clinical signs. Brain MRI, echocardiography, skin examination and genetic testing should be performed early in every patient suspected of having TSC.